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The international project to fully sequence the human genome is close to com-
pletion. We can expect that the resulting information will greatly expand the 
possibilities for diagnosing genetic traits (at least partly) responsible for the in-
cidence of diseases. There are also signs of technological developments which 
could considerably simplify the use of »genetic tests« in medical practice (DNA 
chips). This potentially opens up the prospect of routine use of genetic tests in 
many areas of health care. These prospects and the emerging medical and ethical 
problems already apparent in the current use of genetic diagnosis, together with 
the many dangers of misuse are the reasons why TAB, at the suggestion of the 
rapporteurs for Technology Assessment in the German Bundestag Committee 
for Education, Research and Technology Assessment, has returned to the topic 
of »the status and prospects for the use of genetic tests« within the framework of 
its monitoring activities (TAB submitted an earlier report on genetic diagnostics 
in 1993).
THE STATUS OF HUMAN GENOME RESEARCH
Sequencing of a base or reference genome will bring us closer to the declared 
goal of international human genome research of using the structure of the hu-
man genome to explain the function of individual genes, but will still leave us 
well short of achieving it. The »reference genome« describes the genetic material 
common to humans and allows for comparison with the genome of other organ-
isms. However, to understand the function of individual genes, and particularly 
the mutations involved in the etiology of disease, genetic differences between hu-
man beings – i.e. the variation within the genome – are more important. In med-
ical and pharmaceutical terms, disease-related genetic variations are particularly 
important. To understand such variations and their medical significance, a num-
ber of different research strategies are currently being pursued internationally.
There is scientific agreement that mere knowledge of the sequence of genes or 
proteins has little explanatory value on its own, even if, at times, this was hardly 
ever mentioned in the debate on genome research, as a result of the concen-
tration on sequencing. With the progress in the international human genome 
project, the focus is increasingly on the complexity of the actual task, explaining 
the function of genes. One question here is the fundamental suitability of the 
systematic »big science« projects with their primarily quantitative approach for 
reaching a basic understanding e. g. of the pathological processes.
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Systematic genome research generally is accordingly in a relatively early stage. 
The overwhelming majority of the drugs and therapies on the market in any case 
are still not based on the actual Human Genome Project (HGP). The most con-
crete methodological-technical and »material« inspirations and influences have 
been in the field of genetic diagnostics.
Major advances have been made in diagnosing infections and tumours, and 
these already have great practical significance. DNA analysis techniques have 
gained broad acceptance in the field of pathogen diagnostics and have probably 
had the most concrete benefits for medicine in this area to date. There are also 
diverse possibilities for using DNA analysis in differential diagnosis of cancers. 
As cancer always involves changes at the level of DNA, chromosome and DNA 
analysis techniques are suitable for early identification, progress monitoring and 
controlling the success of therapy.
For some years pharmacogenomics and toxicogenomics have figured in pro-
fessional circles as highly promising applications of genome research in other 
areas of research and possibly medicine. The goal of this research area is to de-
tect genetically-caused differences in metabolising drugs and toxins, in order to 
utilise them to improve prevention and therapy. The vision of pharmacogenetic 
research is to use analysis of genetically-caused differences concerning the ability 
to metabolise chemical substances with the goal to develop drugs for specific 
groups of patients, or to select from the available drugs those which are optimal 
for individual patients – i.e. which have the maximum effect along with mini-
mum side effects. Despite the overall minimal state of knowledge at this stage, 
the pharmaceutical industry is showing great interest, given the substantial eco-
nomic potential in pharmacogenomics.
In the narrower field of genetic diagnostics, the main focus of hopes and fears 
is diagnosis of multifactorial diseases affected by a number of genes and envi-
ronmental influences. Most of the widespread diseases – cancer, cardiovascular, 
metabolic (including diabetes) and neurodegenerative diseases (Alzheimer) – 
have multifactorial etiology. It is expected that research into the human genome 
will open up a new dimension of understanding of the role of genes in the inci-
dence of the diseases listed. In clinical practice, however, diagnosis using human 
DNA is still very largely limited to single-gene inherited diseases. Examples of 
real use of possible tests for multifactorial diseases are still limited at present to 
a small number, the most frequently cited being proof of mutations in the BRCA 
genes causing breast cancer and the association of ApoE variants with a risk of 




A typical feature of all forms of genetic diagnosis for multifactorial diseases or 
disposition to disease is the limited information they provide, as they show only 
an increased risk of a disease and not a reliable prognosis. The value of the typ-
ical information from gene tests – a corresponding genetic characteristic means 
that the patient has a certain probability of contracting disease x by a given 
age – appears highly doubtful, at least where no reliable or tolerable therapy is 
available.
It is, however, not unlikely that genetic testing will be extended in future to 
multifactorial disposition to disease. First, the next few years will probably 
see growing research into dispositions which it makes sense to test for, i.e. are 
amenable to preventive therapy. Second, it must realistically be expected that 
largely pointless tests may also establish themselves. Past experience shows that 
many diagnostic and therapeutic procedures are used (and also funded by the 
health insurance schemes) whose purpose has never been scientifically convinc-
ingly demonstrated or even evaluated.
HUMAN GENETIC COUNSELLING AND DIAGNOSIS
The number of diseases and handicaps with known genetic causes has grown 
steadily in recent years. A range of new genetic tests is also used in genetic 
counselling at university institutes and by human genetics specialists in pri-
vate practice. The overwhelming majority of these are (still) tests for relatively 
rare single-gene inherited diseases. However, genetic tests for breast cancer and 
Alzheimer’s are also being used. The problem of using tests like these, which can 
only identify an increased risk of the disease, is being intensively debated by the 
professional associations and the Federal Medical Council, as there are gener-
ally only drastic preventive measures (in the case of breast cancer) or no useful 
measures at all available if the diagnosis is positive. The general expectation in 
professional circles is that the range of predictive diagnostic products available 
for multifactorial diseases will increase in future. This will increase the number 
of questions about the value or otherwise of using such test products. Because of 
the limited information provided by such tests, qualified human genetic counsel-
ling is regarded as essential.
Whether qualified counselling can be ensured in future is doubtful if the test pos-
sibilities continue to expand and tests become so technically simple and cheap 
that they can be used by non-specialists working with private diagnostic labora-
tories. The technological prerequisite for this is met by the development of the 
DNA chip, which potentially permits several hundred genetic tests to be carried 
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out in a single automated process. Whether genetic tests will become routine 
in general medical practice (other than genetic counselling) is highly doubtful, 
given the limited informational value of many tests. The current problems in test 
practice do, however, give grounds for concern that genetic tests may come to be 
used on the principle that »if it can be diagnosed, it should be«.
PRENATAL DIAGNOSIS
This is particularly applicable to prenatal diagnosis of genetically caused diseas-
es and handicaps in the foetus as part of preventive examinations in pregnancy. 
Prenatal diagnosis (PD) using amniocentesis and chorionic biopsy has steadily 
developed into a routine procedure for pregnant women since the end-70s. The 
original age indication limiting prenatal diagnosis to women over 35 has now 
largely disappeared in practice, so that every pregnant woman is notified of the 
possibility of PD by her gynaecologist. The expansion of the use of PD has been 
driven by the so-called »triple test«, which makes it possible to identify an in-
creased risk of chromosomal anomalies in a foetus from an examination of the 
mother’s blood. Although this test is under severe criticism from human geneti-
cists for its lack of validation and frequent false positive (and negative) results, it 
is offered by many gynaecologists as a »safety first« test, which is often followed 
by a (frequently unnecessary) amniocentesis.
The use of genetic diagnostics in PD is already revealing substantial problems 
with the quality of counselling. In the overwhelming majority of cases the diag-
nosis is ordered by the gynaecologist, and in part carried out in his own labora-
tory. The quality and scope of counselling are often deficient. A free, individual 
decision for or against performance of a genetic tests requires comprehensive 
information of the patient. There is general agreement that this is often not 
available in PD practice.
Women’s associations and many self-help groups for the handicapped reject PD 
as a standard part of preventive medicine in pregnancy. They claim it is not med-
ically justified, leads to unnecessary stress on women and harbours a trend to-
wards discrimination against the handicapped. The demand for an improvement 
in counselling (including psycho-social counselling) is often linked to the desire 




A new potential application for genetic diagnosis is in vitro fertilisation. In so-
called pre-implantation genetic diagnosis (PGD) artificial insemination is com-
bined with examination to identify genetic alterations not in the foetus in utero 
but in egg-cells or in vitro in embryos in an early stage of development. Embryos 
or egg-cells in which the target genetic characteristic is found are selected, while 
those without the target characteristic are transferred to the woman’s uterus.
The procedure, which has now been used in several hundred cases worldwide, 
has led to a debate in Germany about the Embryo Protection Act. While PGD 
was previously regarded unanimously as prohibited by the Embryo Protection 
Act, an increasing number of comments have recently either cast doubt on the 
relevance of the Act’s provisions (which would mean that PGD is allowed) or 
called for reforms to the Act (to make possible PGD in Germany). The proce-
dure – according to the proponents of PGD – could save parents who are aware 
of the genetic risk and (possibly) have already terminated a pregnancy after a 
positive result from a prenatal diagnosis, from having to terminate another preg-
nancy. Critics of PGD point to the right of the embryo to protection against any 
kind of manipulation, and regard PGD as opening the door to selective positive 
eugenics.
It is to be expected that technical advances will make it possible to perform PGD 
at a stage of embryonic development where the provisions of the Embryo Protec-
tion Act no longer apply. A point to be clarified is whether the claims of parents 
with an acknowledged risk justify abandoning the fundamental protection of 
the human embryo against »exploitative« interference which is the intent of the 
Embryo Protection Act.
GENE TESTS IN EMPLOYMENT
Genetic tests at DNA level to predict individual risk of disease and vulnerability 
are not performed in occupational medicine, as far as is known. However, there 
are tests available at the gene product level which demonstrate reduced capacity 
to break down toxins. In addition, analyses at the DNA and chromosome level 
are being used to identify previously incurred injury do to the workplace envi-
ronment.
The debate about the use of genetic tests at the workplace centres primarily on 
the danger that subjective workplace safety, i.e. excluding individuals with ge-
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netically-caused hypersensitivities from jobs, could take priority over objective 
workplace safety, i.e. removing hazardous materials from the work process. The 
practice of biomonitoring for early identification of already incurred damages 
in hazardous jobs can be regarded as in the interest of the employee and is not 
at issue.
The debate about the use of genetic tests at the workplace centres primarily on 
the danger that subjective workplace safety, i.e. excluding individuals with ge-
netically-caused hypersensitivities from jobs, could take priority over objective 
workplace safety, i.e. removing hazardous materials from the work process. The 
practice of biomonitoring for early identification of already incurred damages 
in hazardous jobs can be regarded as in the interest of the employee and is not 
at issue.
The central question in a precautionary regulation could then be how potential 
benefits of these test technologies can be achieved for workplace safety without 
justifying concerns about employee selection, discrimination and nullification of 
objective workplace safety.
GENE TESTS FOR INSURANCE
The use of genetic testing in connection with health insurance and life insurance 
has been a matter of controversy for years. In practice, no use has so far been 
made of information from genetic tests in issuing insurance policies, at least in 
Germany.
Views differ on the question how far it makes sense for insurance companies to 
modify insurance premiums for an individual on the basis of »genetic risk« as 
shown by genetic test results. Insurers claim that there is no actuarial point in 
partitioning the group of policy holders into small groups by risk, so that ac-
tive use of genetic diagnosis is not intended. However, they reserve the right to 
demand disclosure of results from genetic diagnosis if these should reveal that 
applicants are using their knowledge of personal genetic risk to take out large 
policies.
The critical response to this is that it could very well make sense for insurance 
companies to set premiums on the basis of (genetically caused) risk of disease, 
and that there is at least a danger that applicants with presumed high risk would 
only be able to take out a life or health insurance policy on unfavourable terms, 
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or would be forced out of the private health insurance schemes and into the stat-
utory health insurance schemes.
Reports from the UK, claiming that local insurers have abandoned their former 
reservations about the use of genetic tests and intend to ask applicants if genetic 
tests are available, indicate that the situation could change rapidly in Germany 
as well. Currently, there is no legal obstacle in Germany to any demand by in-
surance companies for disclosure of genetic data. The possibility cannot be ruled 
out that with growing use of genetic tests in medicine as a whole, applicants will 
exploit their knowledge of their genetic constitution either to demand favour-
able premiums or to conceal their knowledge of genetic risks to take out large 
policies.
NEED FOR REGULATION
Advances in human genome research will put the question, debated back in the 
early 90s, concerning statutory regulation of the use of genetic diagnostics in a 
new light. First, there are the problems which emerged during the 90s of ensur-
ing the quality of human genetic counselling and diagnostics (particularly in the 
context of prenatal diagnosis), and second there are the increasingly concrete 
possibilities for using genetic tests for widespread diseases (even if – or because 
– the medical benefit of tests for multifactorial diseases is doubtful), all of which 
indicate the need for federal statutory regulation. Given the pace of development 
in the field of genetic diagnostics, the professional regulations currently applying 
in Germany could require backing and closer definition through a Genetic Diag-
nostics Act, to ensure that genetic diagnostics is limited to medical purposes and 
that the quality of diagnosis and counselling is ensured by licensing laboratories 
and counselling services, tying their performance to the right of self-determina-
tion, preventing abuse of genetic data by third parties, and preventing discrimi-
nation against the handicapped.
In the insurance sector, regulation is indicated to prevent discrimination against 
individuals who have had genetic tests carried out. An issue of central impor-
tance in terms of the use of genetic tests at the workplace is statutory definition 
of the right of the employer to request information, the restriction of testing 
practice to tests which are in the interests of the employee or necessary to pro-
tect third parties, and ensuring data protection and voluntary participation in 
testing.
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